Genome-wide Association Study of Methotrexate-Induced Liver Injury in Rheumatoid Arthritis Patients

Frank Eektimmerman, Jesse J. Swen, Alfons A. den Broeder, Johanna M.W. Hazes, Fina S. Kurreeman, Suzanne M.M. Verstappen, Nisha Nair, Andrzej Pawlik, Mike T. Nurmohamed, Vita Dolžan, Stefan Böhringer, Cornelia F. Allaart, Henk Jan Guchelaar*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

34 Downloads (Pure)

Abstract

Hepatotoxicity is a serious adverse drug reaction related to methotrexate (MTX). However, the cause of drug-induced liver injury (DILI) is still unclear and unpredictable. Genetic risk factors may predispose for MTX-DILI. Therefore, we conducted a nested case-control genome-wide association study to explore genetic risk factors associated with MTX-DILI. Seven international groups contributed blood samples and data of patients with rheumatoid arthritis who used MTX. MTX-DILI was defined as an alanine aminotransferase (ALT) level of at least three times the upper limit of normal (ULN), to increase contrast controls ALT levels did not raise above two times the ULN. Per study site, control subjects and patients with MTX-DILI (ratio 3:1) were matched for age, gender, and duration of MTX use. Patients were genotyped using Illumina GSA MD-24v1-0 and data were imputed using the 1000 Genomes reference panel. Single-nucleotide polymorphisms (SNPs) were analyzed using an additive genetic model, corrected for sex, country, and age. A P-value of ≤ 5 × 10−8 was considered significant, whereas a P-value of ≤ 5 × 10−6 was considered suggestive. A total of 108 MTX-DILI cases and 311 controls were included for association analysis. None of the SNPs were significantly associated with MTX-DILI. However, we found seven suggestive genetic variants associated with MTX-DILI (P-values 7.43 × 10−8 to 4.86 × 10−6). Of those, five SNPs were in the intronic protein-coding regions of FTCDNL1, BCOR, FGF14, RBMS3, and PFDN4/DOK5. Investigation of candidates SPATA9 (rs72783407), PLCG2 (rs60427389), RAVER2 (rs72675408), JAK1 (rs72675451), PTPN2 (rs2476601), MTHFR C677T (rs1801133), and into the HLA region did not show significant findings. No genetic variants associated with MTX-DILI were found, whereas suggestive SNPs need further investigation.

Original languageEnglish
Pages (from-to)916-923
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume113
Issue number4
Early online date27 Jan 2023
DOIs
Publication statusPublished - Apr 2023

Bibliographical note

Funding Information:
No funding was received for this work. The authors would like to thank Yavuz Ariyurek for his technical advice concerning performing the GWAS. In addition, we show our gratitude to Jip Linthorst for the preliminary research for causes of DILI and to Renée Baak-Pablo, Daniëlle Klootwijk, and Rowena Schaap for the preparation of the GWAS.

Funding Information:
S. Verstappen and N. Nair are supported by Versus Arthritis (grant numbers 20385 and 20380) and the NIHR Manchester Biomedical Research Centre, UK. All other authors declared no competing interests for this work.

Publisher Copyright:
© 2023 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Fingerprint

Dive into the research topics of 'Genome-wide Association Study of Methotrexate-Induced Liver Injury in Rheumatoid Arthritis Patients'. Together they form a unique fingerprint.

Cite this